As Antibiotics Recover, Centrient Maintains Focus On Sustainability
CEO Discusses Antibiotics Market, AMR, Manufacturing And European Pressures
Executive Summary
As the antibiotics market recovers in the wake of the COVID-19 pandemic, Centrient CEO Rex Clements talks to Generics Bulletin about the firm’s recent sustainability milestones as well as the cost and policy challenges faced by European manufacturing.
You may also be interested in...
Industry Speaks Out On Global Antibiotics Shortages
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”
Accord And Sandoz Lead Victories At GGB Awards 2022
Accord and Sandoz were the big winners at the Global Generics & Biosimilars Awards 2022 in Frankfurt, with other firms recognized including Beximco, Centrient, Dr Reddy’s, Eurofarma, Samsung Bioepis, Shanghai Henlius Biotech and Stada, as well as the US Biosimilars Forum.
EU Drug Supply In Jeopardy Without Energy Support, Warns Medicines For Europe
Medicines for Europe calls for the pharmaceutical industry to be excluded from energy restriction policies for winter 2022 in an open letter to EU governance bodies. Inflation and energy costs threaten European drug makers with closures and rationing, says the industry body.